All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
Clover is the second Chinese developer to apply for Phase 3 clinical trials in the Philippines following Sinovac Biotech, which is seeking to begin trials of its vaccine as early as next month.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animals and protects nonhuman primates from SARS-CoV-2 challenge.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JS016
Therapeutic Area: Infections and Infectious Diseases Product Name: JS016
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2020
Details:
The study is a randomized, double-blind, placebo-controlled Phase I trial is intended to investigate the safety and tolerability of single dose JS016 intravenous injection (IV) in 40 healthy subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): S-Trimer COVID vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: Undisclosed Upfront Cash: $66.0 million
Deal Type: Funding July 08, 2020
Details:
Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 S-Trimer vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020
Details:
First participants have been dosed in the Phase 1 first-in-human study evaluating the company’s COVID-19 S-Trimer subunit vaccine candidate (SCB-2019), which is based on Clover’s proprietary Trimer-Tag© vaccine technology platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JS016
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2020
Details:
JS016 is a recombinant fully human monoclonal neutralizing antibody that blocks the binding of the SARS-CoV-2 virus to the host cell surface receptor ACE2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adenovirus vector based SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2020
Details:
The vaccine candidate met the initial end points regarding adverse events and safety and provide evidence of immunogenicity against the target protein.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
The Canadian Center for Vaccinology at Dalhousie University has received approval from Health Canada to conduct the country’s first clinical trials of a potential Covid-19 vaccine, Ad5-nCoV, developed under CanSino Biologics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
Details:
Joint developers submitted pre-investigational new drug review application for AD5-NCOV to regulatory authorities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TJM2
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2020
Details:
The development will start following the FDA acceptance of I-Mab’s Investigational New Drug application, and the study will commence initially in the U.S. with plans to expand into other countries.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
